Spectral AI Inc

Análisis de la acción Spectral AI Inc (MDAI)

$1.495

+0.125 (+8.33%)Al cierre

Loading chart…
Máximo
1.530
Apertura
1.410
Precio medio ponderado por volumen
1.47
Volumen
166.46K
Capitalización
31.47M
Mínimo
1.400
Importe
245.53K
EV/EBITDA, TTM
-1.19

Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image.

Análisis de IA of Spectral AI Inc (MDAI)

Comprar

Spectral AI Inc is a good buy right now due to its recent FDA clearance for the DeepView System, which is expected to drive revenue growth, with an anticipated revenue of approximately $18.5 million for the year. The current price is $1.52, significantly below the analyst price target of $4, indicating a potential upside of 163.16%. However, the company has a high forward P/E of 52.36, indicating potential valuation concerns as it continues to navigate operational losses.

Métricas de valoración

El PER previsto actual de Spectral AI Inc (MDAI) es 52.36, frente a su media de 5 años de 6.80.

PER previsto

Muy sobrevalorado
Media 5A P/E
6.80
P/E actual
52.36
Sobrevalorada
25.58
Infravalorada
-11.98

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
-18.84
EV/EBITDA actual
-1.19
Sobrevalorada
3.75
Infravalorada
-41.44

Precio/ventas previsto

Valor razonable
Media 5A P/S
4.76
P/S actual
1.37
Sobrevalorada
9.54
Infravalorada
-0.02

Escenarios de precio de Alphio AI para MDAI

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%MDAI

$2.22

Precio del escenario

B

Base

Base · 50%MDAI

$2.20

Precio del escenario

B

Bajista

Bajista · 25%MDAI

$1.52

Precio del escenario

Cronología de eventos

2026-10-06 (ET)

09:00:00

Spectral AI Submits NTAP Application to CMS

2026-10-01 (ET)

09:00:00

Spectral AI Completes First Site Initiation Visit for Clinical Study

2026-07-08 (ET)

09:30:00

Spectral AI Appoints Darcy Bajko as Chief Commercial Officer

2026-05-26 (ET)

07:10:00

Spectral AI's DeepView System Receives FDA De Novo Classification

2026-04-08 (ET)

08:50:00

Spectral AI Appoints David McGuire as CFO

Noticias

Preguntas frecuentes sobre MDAI, respondidas por Alphio AI

Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Spectral AI Inc is a good buy right now due to its recent FDA clearance for the DeepView System, which is expected to drive revenue growth, with an anticipated revenue of approximately $18.5 million for the year. The current price is $1.52, significantly below the analyst price target of $4, indicating a potential upside of 163.16%. However, the company has a high forward P/E of 52.36, indicating potential valuation concerns as it continues to navigate operational losses.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar